Independent and not affiliated with the FDA, MHRA, ISPE, PDA, or any agency. Get the appgoutham@madhadi.com
madhadi.comData Integrity & GxP Quality
Browse all topics → Articles Templates & Procedures Learning paths GlossaryScenariosToolsRegulatory ReferencesLearning PathsTopics About Start here
Checklist Plug-and-play starting point Quality Assurance

Checklist: Complaint File Inspection Readiness Review

A per-file and system-level readiness check for product complaint records: verbatim capture, adverse event screening, lot pursuit, severity and reportability rationale, investigation proportionality, CAPA linkage, timeliness, reply to complainant, retention and retrievability, plus trending, thresholds, backlog age, and classification consistency, with a filled specimen.

Document type: Checklist

Read and copy the template below into your own quality system. It is a generic starting point for your own internal use, provided as is, with no warranty; see the Terms and License. Adopting it does not by itself create compliance.

This is a ready-to-use readiness check for complaint records, run before an inspection rather than during one. It has two parts: a per-file review that samples individual complaint records, and a system-level review of the things an inspector will ask about the programme as a whole. Replace every <<FILL: ...>> placeholder, set your own document numbers and dates, and route it through your normal document control before use. A worked filled specimen follows.

This document is educational and is written to be adapted. Confirm every cited regulation against the current published source, and confirm your own reporting obligations with your regulatory affairs and pharmacovigilance functions. Passing this checklist does not by itself demonstrate compliance; it surfaces the gaps you still have time to close.

The premise: an inspector will pull a small number of complaint files, usually chosen to be awkward, and read them end to end. What they are testing is whether the record shows a decision being made by a qualified person on stated facts, at each of the points where a decision was required. Files fail not because the work was not done but because the record does not show it was done. Run this check on your own files first, while you can still fix what it finds.

Use it with the complaint handling SOP, the reportability decision matrix, the investigation report form, and the trending log. For the broader inspection posture, see inspection readiness and the system-level inspection readiness checklist.

Document control header

FieldEntry
Document titleComplaint File Inspection Readiness Review
Document number<<FILL: DOC-ID, e.g. QA-CHK-031-05>>
Version<<FILL: version, e.g. 1.0>>
Effective date<<FILL: effective date>>
Document owner<<FILL: role, e.g. Head of Quality Assurance>>
Governing SOP<<FILL: SOP-ID for complaint handling>>
Review frequency<<FILL: e.g. quarterly, and before any anticipated inspection>>
Reviewer independence<<FILL: e.g. performed by QA staff who did not handle the sampled complaints>>

How to use this checklist

  1. Sample deliberately, not conveniently. Pull the files an inspector would pull. The sampling rule is in section 1.1.
  2. Score each line Pass, Fail, or NA. NA requires a reason. A line that cannot be scored because the record is ambiguous is a Fail, not an NA: if a reviewer with full access and unlimited time cannot tell, an inspector reading it cold will not be able to either.
  3. Score from the record only. Do not credit a line because you know the work was done or because the person who did it is standing next to you. If it is not in the file, it did not happen for the purposes of this check.
  4. Record the evidence location for every Pass, not just for every Fail. Being able to point at the page is half of what inspection readiness is.
  5. A single Fail on a critical line fails the file. Critical lines are marked with an asterisk. They are the ones that carry a patient-safety or legal-deadline consequence.
  6. Findings go to CAPA, not to a list. A readiness review that generates observations with no owner and no due date will generate the same observations next quarter.

1.1 Sampling rule

Pull at least <<FILL: e.g. 20>> complaint files per review, selected to include all of the following:

SelectionMinimumWhy an inspector will pull these
Complaints with an associated adverse event<<FILL: e.g. 3>>The highest-consequence interface in the system
Complaints closed as unconfirmed or “could not confirm”<<FILL: e.g. 4>>The known closure shortcut
Complaints closed with no investigation<<FILL: e.g. 2>>, or all if fewerThe justification and attribution requirement
Complaints closed as user or handling error<<FILL: e.g. 2>>The recurring design or labelling question
Complaints where a report was submitted<<FILL: e.g. 2>>Timeliness against the clock
Complaints assessed as not reportable<<FILL: e.g. 3>>Whether the rationale exists at all
Complaints closed late or with an extension<<FILL: e.g. 2>>, or all if fewerTimeliness and extension governance
Complaints on a lot with more than one complaint<<FILL: e.g. 2>>Whether the cluster was linked
Complaints without a lot number<<FILL: e.g. 2>>, or all if fewerWhether the lot was pursued
Complaints on contract-manufactured product<<FILL: e.g. 2>>, or all if fewerQuality agreement performance
Oldest open complaint currently in the system1Backlog
Most recent closed complaint1Current practice, not historical practice

Sampling only closed, tidy, confirmed complaints produces a readiness review that passes and an inspection that does not.


Section 1: Per-file review

Complete one column set per file. Reproduce the table per file, or use one row per file per line item in a spreadsheet, whichever suits your record system.

FieldEntry
Complaint number<<FILL>>
Product and lot<<FILL>>
Date of awareness / date closed<<FILL>> / <<FILL>>
Severity as closed<<FILL>>
Reviewer<<FILL>>
Review date<<FILL>>

1.2 Intake and capture

#CheckPass / Fail / NAEvidence locationNote
1.2.1The complainant’s account is recorded verbatim, in their own words, and is distinguishable from the categorised summary.
1.2.2The verbatim text has not been overwritten, replaced by a category code, or edited without an audit trail.
1.2.3Date and time of awareness are recorded, and where they differ from the date logged, both appear and the gap is explained.
1.2.4The complaint received a unique number at first contact, before triage.
1.2.5Reporter type and contact details are recorded, or “declined” or “anonymous” is recorded explicitly rather than the field being blank.
1.2.6Product, strength, and presentation are recorded and correspond to a product the company actually markets.
1.2.7Sample availability is recorded, and where a sample could be returned, the request and the outcome are recorded.
1.2.8The record was made contemporaneously, and any oral complaint was written down at the time of the call.

1.3 Adverse event screening

#CheckPass / Fail / NAEvidence locationNote
1.3.1*The adverse event screen was completed and every question carries an answer. A blank screen is a Fail.
1.3.2*Where any answer was Yes or Unclear, the case was referred to pharmacovigilance, and the referral date, time, recipient, and safety case reference are in the file.
1.3.3The referral was made on the day of awareness, or the delay is recorded and explained.
1.3.4The referral was not made conditional on the quality investigation, the laboratory result, or confirmation of the defect.
1.3.5Pharmacovigilance acknowledgement is recorded.
1.3.6Where the screen was negative, the negative answers are recorded rather than the section being left empty.
1.3.7Where a special situation was reported (pregnancy, lactation, overdose, medication error, misuse, off-label use, lack of effect), it is recorded and routed.
1.3.8The intake handler did not assess seriousness, expectedness, or causality themselves.

1.4 Lot number and traceability

#CheckPass / Fail / NAEvidence locationNote
1.4.1A lot number is recorded.
1.4.2*Where no lot number was obtained, the file records what was asked, what alternatives were tried (carton photograph, dispensing record, pharmacy or wholesaler trace, distribution records for the location), and the outcome. A blank is a Fail.
1.4.3Where a lot number is recorded, it corresponds to a real lot of that product, and the expiry date is consistent with it.
1.4.4The batch record, certificate of analysis, and reserve sample location for the lot are identified in the file or reachable from it.
1.4.5The markets the lot was distributed into are identified, from distribution records rather than from the product’s general market footprint.

1.5 Severity classification

#CheckPass / Fail / NAEvidence locationNote
1.5.1A severity is assigned.
1.5.2*The specific facts driving the severity are recorded, not just the tier. A tier with no basis is a Fail.
1.5.3The severity is consistent with the anchored definitions and examples in the governing SOP.
1.5.4Where severity was changed after triage, the original value, the new value, the reason, the approver, and the date all appear.
1.5.5The severity was assigned by QA, not by intake.
1.5.6Severity was assigned on the alleged defect at triage, not deferred until the investigation concluded.

1.6 Reportability

#CheckPass / Fail / NAEvidence locationNote
1.6.1*A reportability assessment exists, including where the conclusion was “not reportable”.
1.6.2*The assessment names the regulations considered and records a conclusion for each branch, including the branches assessed as not applicable.
1.6.3*Each conclusion carries a rationale in facts, not a category code. “Not reportable, cosmetic” is a Fail; a statement of what was and was not affected is a Pass.
1.6.4*The assessment is attributable: a named person with an appropriate role and a date.
1.6.5*The assessment was made at or near intake, inside the shortest applicable regulatory clock, not only at closure.
1.6.6Day zero is recorded as the date of company awareness, not the date the complaint reached quality assurance.
1.6.7*Where a report was submitted, the report reference and the submission date appear in the complaint file, and the submission was inside its clock.
1.6.8Reportability was reassessed at investigation close, and the outcome of that reassessment is recorded.
1.6.9Where the lot was distributed into more than one market, each market’s obligation was considered.
1.6.10Where the product is a combination product and the device constituent was implicated, the constituent-part obligations were assessed.

1.7 Investigation

#CheckPass / Fail / NAEvidence locationNote
1.7.1The decision on whether to investigate is recorded.
1.7.2*Where the decision was not to investigate, a justification is recorded together with the name and role of the responsible person who made it.
1.7.3Investigation depth is proportionate to the severity, and the proportionality decision is recorded rather than inferred.
1.7.4An investigation plan exists and predates the results.
1.7.5Where a sample was received, its condition on receipt is documented before handling, with photographs.
1.7.6Identity of the returned unit was confirmed before testing.
1.7.7Testing was against the release specification the lot was released to, and the specification is stated alongside each result.
1.7.8The batch record and deviation history for the lot were reviewed, with findings and record references.
1.7.9Where a deviation on the lot had previously been closed as “no impact”, that conclusion was reassessed against the attribute now in question rather than cited.
1.7.10*A cluster and trend check on the lot and the defect type was performed, and the result including a nil result is recorded.
1.7.11Prior complaints on the same lot are linked, not left as unconnected records.
1.7.12Root cause is stated, or where it was not determined, what was ruled out and on what evidence is recorded, together with a plan to detect a recurrence.
1.7.13*Where the conclusion is unconfirmed or not determinable, the file shows what was still done: reserve sample examination, batch record review, cluster check, and plausibility assessment. “No sample, closed” is a Fail.
1.7.14Where the conclusion is that the returned sample passed, the file addresses whether the release test could have detected the alleged defect at all.
1.7.15Where the cause was recorded as user or handling error, the file records whether the labelling, packaging, or instructions for use invite the error.
1.7.16*Product impact was assessed for the lot, for adjacent lots sharing the suspected cause, and for other products, with the bounding stated.
1.7.17*The need for a field action was explicitly assessed, and where the answer was no, the reasoning is recorded.
1.7.18The conclusion is supported by evidence referenced in the file, not asserted.
1.7.19Where the product was made under contract, what was requested from the contract partner, when, and what was received are recorded.

1.8 CAPA linkage

#CheckPass / Fail / NAEvidence locationNote
1.8.1A CAPA decision is recorded, in both directions. A bare “No” with no reasoning is a Fail.
1.8.2Where a CAPA was opened, the reference appears in the complaint file and the complaint number appears in the CAPA record.
1.8.3Where the CAPA arose from a trend, all contributing complaints are linked to it.
1.8.4An effectiveness measure is defined, in the same terms as the signal that triggered the CAPA.
1.8.5Where no CAPA was opened on a confirmed complaint with an identified correctable cause, the reasoning is recorded and is defensible.
1.8.6Where a Critical complaint was closed with no CAPA, the reasoning is recorded and approved at the level the SOP requires.

1.9 Timeliness

#CheckPass / Fail / NAEvidence locationNote
1.9.1The complaint was recorded and numbered within the procedural target from the date of awareness.
1.9.2Triage was completed within the procedural target.
1.9.3The investigation started and closed within the target for its severity.
1.9.4*Where a target was missed, an extension is recorded with a reason, a revised date, an approver, and a date of approval that precedes the original target date.
1.9.5Where a regulatory report was submitted, it was submitted inside its clock, counted from the date of awareness.
1.9.6Internal routing time did not consume the regulatory clock without being visible in the record.

1.10 Reply to the complainant

#CheckPass / Fail / NAEvidence locationNote
1.10.1Whether a reply was due is recorded.
1.10.2Where a reply was due, the date, method, and a summary of what was said are recorded.
1.10.3The reply is consistent with the investigation conclusion and does not overstate or understate it.
1.10.4The reply does not disclose confidential investigation detail, other complainants, or other patients.
1.10.5Where the complaint carried an adverse event, the reply wording was coordinated with the function qualified to make any clinical statement.
1.10.6Where no reply was due, the reason is recorded.

1.11 Record completeness, retention, and retrievability

#CheckPass / Fail / NAEvidence locationNote
1.11.1The file contains everything needed to reconstruct the history without asking anyone: number, dates, reporter, product and lot, verbatim nature, whether investigated and the justification if not, findings, reportability decision and report references, CAPA reference, and the reply.
1.11.2Closure is approved by QA, with a name and date.
1.11.3No field is blank where an entry or a recorded “N/A with reason” is required.
1.11.4Corrections are made by strike-through with initials, date, and reason on paper, or through the audit-trailed function in the electronic system, with no overwriting or obliteration.
1.11.5The record is within its retention period and the applicable retention rule is identifiable.
1.11.6The complete file, including attachments, photographs, and test data, was retrieved within <<FILL: e.g. 15 minutes>> of request during this review.
1.11.7Where the complaint was handled at a location other than the manufacturing establishment, the records are reasonably accessible at the manufacturing establishment.
1.11.8Cross-references to deviation, out-of-specification, CAPA, safety, and recall records resolve to real records that exist and point back.

1.12 Per-file result

FieldEntry
Lines scored<<FILL>>
Pass / Fail / NA counts<<FILL>> / <<FILL>> / <<FILL>>
Critical (asterisked) lines failed<<FILL: list, or "none">>
File resultPass / Fail (any critical-line Fail = Fail)
Findings raised<<FILL: reference>>

Section 2: System-level review

The per-file review tests execution. This section tests the programme. An inspector who finds tidy individual files will still ask these questions.

2.1 Procedure and governance

#CheckPass / Fail / NAEvidenceNote
2.1.1A current, approved, effective complaint handling procedure exists and covers written and oral complaints.
2.1.2The procedure defines severity tiers with anchored definitions and examples, not tier names alone.
2.1.3The procedure defines timelines for each step and each severity, and those timelines are numbers rather than “promptly”.
2.1.4Intake staff are procedurally prevented from closing, dismissing, or downgrading a complaint.
2.1.5Everyone performing intake, triage, investigation, and reportability assessment is trained to the current version, with training records available.
2.1.6The reportability matrix is current, owned jointly with regulatory affairs and pharmacovigilance, and covers every market the products are distributed into.
2.1.7Quality agreements with contract manufacturers and distributors specify complaint notification and response timelines, and those timelines fit inside the regulatory clocks.
#CheckPass / Fail / NAEvidenceNote
2.2.1*Trending is performed on the defined cadence, and records exist for every period in the last <<FILL: e.g. 24 months>> with no gaps.
2.2.2*Rates are normalised to units distributed, and the numerator and denominator definitions are fixed and documented.
2.2.3Lot-level rates use that lot’s distribution as the denominator, not total product distribution.
2.2.4Trending covers defect type, lot, product and presentation, and time, at minimum, and the dimensions are crossed rather than only listed.
2.2.5Unconfirmed complaints are included in the trend, and the inclusion rule is stated and constant.
2.2.6Zero rows are recorded rather than omitted.
2.2.7The data source is a validated report, referenced by name and version, and the extract is retained with the review.
2.2.8Where the analysis runs in a spreadsheet, the spreadsheet is under appropriate control and its calculation has been verified.

2.3 Thresholds

#CheckPass / Fail / NAEvidenceNote
2.3.1*Thresholds are defined in advance, in writing, and approved.
2.3.2The basis for each threshold level is recorded, including the baseline it derives from and why that baseline period was chosen.
2.3.3Baselines are reset on a defined cadence and after any confirmed process change affecting the defect type.
2.3.4Thresholds cover rate-based and count-based triggers, so that low-volume products and young lots are not left without a trigger.
2.3.5*No threshold was raised, or definition changed, in response to a crossing in a way that removed the crossing. Check the revision history, not just the current version.
2.3.6*Every threshold crossing in the last <<FILL: e.g. 24 months>> traces to an investigation or to a recorded, attributed, reasoned decision not to escalate.
2.3.7Effectiveness checks for trend-driven CAPAs are written in the same units as the threshold that triggered them.
2.3.8Signals watched below threshold are recorded, with the watch period and the reason for not escalating.

2.4 Backlog and timeliness

#CheckPass / Fail / NAEvidenceNote
2.4.1Total open complaints: <<FILL>>. Against a defined limit of <<FILL>>.
2.4.2Age of the oldest open complaint: <<FILL>> days. Against a defined limit of <<FILL>>.
2.4.3Open complaints older than <<FILL: e.g. 60 days>>: <<FILL>> (<<FILL>> percent of open). Against a limit of <<FILL: e.g. 5 percent>>.
2.4.4Every complaint past its target has a documented, approved extension dated before the target passed.
2.4.5On-time closure rate for the period: <<FILL>> percent, against a target of <<FILL>> percent.
2.4.6The backlog is not concentrated in one severity, one product, or one handler in a way that indicates an unaddressed resource or capability gap.
2.4.7Backlog and timeliness are reported into management review with a trend, not a single snapshot.

2.5 Classification consistency

#CheckPass / Fail / NAEvidenceNote
2.5.1A consistency check is performed on a defined cadence: a sample of complaints re-coded independently by a second reviewer.
2.5.2Agreement rate for the last check: <<FILL>> percent, against a target of <<FILL>> percent.
2.5.3Severity assigned to the same defect type is consistent across handlers and across periods.
2.5.4The share of complaints coded to “other” is <<FILL>> percent, against a limit of <<FILL>> percent. A rising share means the category list no longer fits what is being reported.
2.5.5Categories that were confused with one another have been identified and addressed through anchored examples or training.
2.5.6Defect categories are aligned across the intake form, the investigation form, and the trending log, so the three cannot disagree.

2.6 Interfaces

#CheckPass / Fail / NAEvidenceNote
2.6.1The complaint-to-pharmacovigilance interface can be demonstrated end to end on a real case, with timings.
2.6.2Reconciliation between the complaint system and the safety database is performed on a defined cadence, so a case in one but not the other is detected.
2.6.3Complaint trends demonstrably reach the annual product review, and last year’s review contains them.
2.6.4Complaint metrics demonstrably reach management review, with decisions and resource allocations recorded.
2.6.5Complaints that escalated to a field action trace cleanly into the recall records, and back.
2.6.6Complaints on contract-manufactured product were notified to the contract partner within the quality agreement timeline, and responses were received within it.

2.7 System-level result

FieldEntry
Lines scored<<FILL>>
Pass / Fail / NA counts<<FILL>> / <<FILL>> / <<FILL>>
Critical (asterisked) lines failed<<FILL>>
System resultPass / Pass with actions / Fail

Section 3: Findings, actions, and signoff

#FindingSource lineSeverityActionOwnerDueReference
<<FILL>><<FILL>><<FILL>>Critical / Major / Minor<<FILL>><<FILL>><<FILL>><<FILL>>
FieldEntry
Files sampled / files passed / files failed<<FILL>> / <<FILL>> / <<FILL>>
Most frequent failure mode across the sample<<FILL>>
Systemic issues identified (a failure appearing in more than one file is systemic, not isolated)<<FILL>>
Actions requiring CAPA rather than local correction<<FILL>>
Readiness statement<<FILL: ready / ready with actions closing by [date] / not ready, with the reason>>
Date the next review is due<<FILL>>
RoleNameSignatureDate
Reviewer<<FILL>>
Complaints Manager<<FILL>>
QA approval<<FILL>>
Head of Quality (readiness statement)<<FILL>>

Filled specimen

The following is a completed review, abbreviated to one representative file plus the system-level section. Company, product, people, and numbers are illustrative. It is deliberately a review that finds real problems, because a readiness review that passes everything has not been run properly.

Review header

FieldEntry
Review referenceRDY-2026-Q2-03
Review date15 July 2026
ReviewerH. Okafor, QA Auditor (did not handle any sampled complaint)
Scope20 complaint files closed between 1 January and 30 June 2026, plus the system-level section
Governing SOPSOP-QA-031 v3.0
TriggerScheduled quarterly review, brought forward ahead of an anticipated inspection

Per-file review, file 7 of 20

FieldEntry
Complaint numberCMP-2026-0688
Product and lotFictional Bio lyophilised biologic 100 mg/vial, lot LB-4417
Date of awareness / date closed14 May 2026 / 2 June 2026
Severity as closedCritical
Selected becauseClosed as unconfirmed, no sample returned
#CheckResultEvidenceNote
1.2.1Verbatim account recordedPassIntake form section D”It looked milky after we mixed it, not clear like usual” recorded in the reporter’s words
1.2.3Date and time of awareness recordedPassIntake form section A14 May 2026, 11:05, logged same day
1.2.7Sample availability recorded, request madePassIntake form section HSample requested during the call; complainant had already discarded the vial
1.3.1*AE screen completed, all questions answeredPassIntake form section EAll five answered, all negative
1.3.2*Referral where positiveNAScreen negative, no referral required
1.4.1Lot number recordedPassIntake form section CLB-4417
1.5.2*Specific facts driving severity recordedPassTriage record”Appearance change on reconstitution of a sterile parenteral biologic; potential purity issue; lot distributed”
1.6.1*Reportability assessment existsPassReportability blockPresent
1.6.2*Regulations named, conclusion per branchFailReportability blockOnly the BPDR branch is addressed. The adverse experience, Field Alert Report, EU, and combination product branches are blank rather than marked not applicable.
1.6.3*Rationale in factsFailReportability blockBPDR conclusion reads “not reportable, unconfirmed”. Unconfirmed status is not a rationale: 21 CFR 600.14 turns on information reasonably suggesting a reportable event, not on confirmation.
1.6.4*AttributablePassReportability blockS. Beniwal, RA, 15 May 2026
1.6.5*Assessed near intakePassReportability block15 May 2026, one day after awareness
1.7.2*No-investigation decision justified and attributedNAAn investigation was performed
1.7.10*Cluster and trend check performed and recordedFailInvestigation recordNo cluster check on lot LB-4417 or on the appearance defect type. Nothing recorded, not even a nil result.
1.7.13*Unconfirmed: what was still doneFailInvestigation recordThe record states “no sample returned, unable to confirm, closed”. No reserve sample was examined, no batch record was reviewed, no plausibility assessment was obtained. Reserve samples for LB-4417 were available in the QC retain store throughout.
1.7.16*Product impact assessed and boundedFailInvestigation recordNot assessed.
1.7.17*Field action explicitly assessedFailInvestigation recordNot assessed.
1.8.1CAPA decision recorded both waysFailClosure record”CAPA: No”. No reasoning.
1.9.3Closed within target for severityPassClosure record19 days against a 30 day Critical target
1.10.2Reply recordedPassClosure recordLetter sent 3 June 2026, summary recorded
1.11.6Retrieved within 15 minutesPassRetrieved in 6 minutes including attachments
FieldEntry
Lines scored41
Pass / Fail / NA32 / 7 / 2
Critical lines failed1.6.2, 1.6.3, 1.7.10, 1.7.13, 1.7.16, 1.7.17
File resultFail
Findings raisedF-2026-Q2-11 through F-2026-Q2-14

Reviewer note on file 7. This file closed on time, with a good verbatim capture, a completed adverse event screen, and a well-reasoned severity. It still fails, and the reason matters: the complaint was closed as unconfirmed on the single fact that no sample was returned, with no reserve sample examined and no cluster check performed. Reserve samples were on site. A second complaint on the same lot arrived three weeks later and was closed the same way. A third arrived on 6 July with a returnable sample and confirmed a purity defect that led to a Class II recall. Both earlier files were individually honest and collectively a detection failure. This is the exact pattern the “could not confirm” line in section 1.7.13 exists to find, and it was found here about six weeks later than it should have been.

Sample-wide result

FieldEntry
Files sampled / passed / failed20 / 13 / 7
Most frequent failure modeReportability branches left blank rather than assessed and marked not applicable: 11 of 20 files (line 1.6.2)
Second most frequentUnconfirmed closures with no reserve sample examination and no cluster check: 5 of the 6 unconfirmed files sampled (lines 1.7.10 and 1.7.13)
ThirdCAPA decision recorded as a bare “No” with no reasoning: 9 of 20 files (line 1.8.1)
Systemic issuesAll three of the above appear across multiple handlers and multiple products. They are procedure and form design issues, not individual performance issues.

System-level review

#CheckResultEvidenceNote
2.1.1Current procedure covering written and oral complaintsPassSOP-QA-031 v3.0, effective 1 Feb 2026
2.1.2Anchored severity definitions with examplesPassSOP-QA-031 section 5.4
2.1.6Reportability matrix current and covering all marketsFailQA-MTX-031-02 v1.0Matrix covers the US only. Three products were launched into Germany and Canada in 2025 and neither market appears. Last reviewed January 2025.
2.2.1*Trending performed on cadence, no gaps in 24 monthsPassTREND-2024-07 through TREND-2026-0624 consecutive monthly records
2.2.2*Rates normalised, definitions fixedPassQA-LOG-031-03 section 2Per 100,000 vials distributed, ship-date basis
2.2.3Lot-level rates use lot distribution as denominatorPassTREND-2026-06-01Verified by recalculation on two lots
2.2.5Unconfirmed complaints included in the trendPassQA-LOG-031-03 section 2.2Stated rule; verified against the June extract
2.3.1*Thresholds defined in advance and approvedPassThreshold set v2.0, approved 6 Jan 2026
2.3.5*No threshold raised to remove a crossingPassRevision history reviewed back to 2024Two changes, both prospective, both with recorded rationale
2.3.6*Every crossing traces to an investigation or a reasoned decisionPass4 crossings in 24 monthsAll four traced; ESC-2026-0031 linked to INV-2026-0311
2.4.2Age of oldest open complaintPass31 days against a 60 day limit
2.4.3Open complaints older than 60 daysPass0 of 14 open (0 percent) against a 5 percent limit
2.4.5On-time closure rateFail84 percent against a 90 percent targetDriven by Minor complaints, where the 60 day target is missed routinely. Either the target or the resourcing is wrong.
2.5.2Classification agreement ratePass90 percent (18 of 20) at the 30 June checkAgainst an 85 percent target
2.5.4Share coded “other”Pass8 percent against a 10 percent limitRising from 5 percent a year ago; watched
2.6.2Complaint and safety database reconciliationFailNo reconciliation is performed. A case present in one system and absent from the other would not be detected by any current control.
2.6.3Trends reach the annual product reviewPassAPR-2025 section 9Complaint rates by defect type present with prior-year comparison
FieldEntry
Lines scored38
Pass / Fail / NA34 / 3 / 1
Critical lines failedNone
System resultPass with actions

Findings and actions

#FindingSourceSeverityActionOwnerDue
F-2026-Q2-11Reportability branches left blank rather than assessed, in 11 of 20 files. Blank is indistinguishable from never considered.1.6.2MajorMake every branch a mandatory field in the complaint system, with a required “not applicable” rationale. Retrain. Retrospectively complete the assessment on the 11 sampled files and on the remaining 2026 population.M. Duarte30 Sep 2026
F-2026-Q2-12Unconfirmed complaints closed with no reserve sample examination and no cluster check, in 5 of 6 sampled. Direct contributor to a six-week delay in detecting a confirmed purity defect on lot LB-4417.1.7.10, 1.7.13CriticalRevise SOP-QA-031 so a no-sample complaint cannot be closed as unconfirmed without a documented reserve sample examination and lot cluster check. Folded into CAPA-2026-0203. Retrospective review of all 2026 unconfirmed closures.T. Nwosu30 Sep 2026
F-2026-Q2-13Reportability matrix covers the US only; Germany and Canada launches from 2025 are absent.2.1.6CriticalRegulatory Affairs to add both markets with local defect and safety reporting obligations and clocks. Add a launch checklist step so no market goes live without a matrix row. Reconcile the matrix against distribution records quarterly.S. Beniwal31 Aug 2026
F-2026-Q2-14CAPA decision recorded as a bare “No” in 9 of 20 files.1.8.1MinorMake the reasoning field mandatory when the CAPA decision is No.M. Duarte30 Sep 2026
F-2026-Q2-15No reconciliation between the complaint system and the safety database.2.6.2MajorEstablish a monthly reconciliation with a documented output and an exception route.Head of PV with M. Duarte31 Oct 2026
F-2026-Q2-16On-time closure at 84 percent against a 90 percent target, concentrated in Minor complaints.2.4.5MinorAssess whether the 60 day Minor target or the resourcing is wrong, and change one of them through document control rather than continuing to miss it.K. Ofori30 Sep 2026
FieldEntry
Readiness statementNot ready. Two Critical findings, F-2026-Q2-12 and F-2026-Q2-13, both carry a patient-safety or regulatory-deadline consequence and both are open. Readiness will be reassessed when those two close, targeted 30 September 2026. The system-level trending and threshold controls are sound and would stand up to examination; the per-file execution and the market coverage of the reportability matrix would not.
Next review due15 October 2026, or on closure of F-2026-Q2-12 and F-2026-Q2-13, whichever is earlier
RoleNameDate
ReviewerH. Okafor, QA Auditor15 July 2026
Complaints ManagerM. Duarte16 July 2026
QA approvalK. Ofori, QA Manager16 July 2026
Head of Quality (readiness statement)J. Sandoval17 July 2026

What the specimen is meant to show. The system-level controls passed almost everything: trending was performed for 24 consecutive months, thresholds were pre-defined and never manipulated, and every crossing traced to an action. The failure was entirely at the per-file level, where blank reportability branches and shortcut closures on unconfirmed complaints were routine, and in one stale document that had never caught up with two market launches. That combination is common. A programme can have an intact architecture and still fail an inspection on execution, and the only way to find out which one you have is to read your own files the way an inspector will.

Common inspection findings this checklist prevents

  • Complaint files that look complete until read closely, where the reportability section is present but blank on most branches.
  • “Could not confirm” closures with nothing behind them: no reserve sample, no batch record review, no cluster check, on files where all three were available.
  • A decision not to investigate with no justification and no name attached.
  • Severity assigned with no recorded facts, or changed after triage with no record of the original value or the approver.
  • Complaints with no lot number and no evidence one was pursued.
  • A reportability decision made only at closure, after the shortest regulatory clock had already run.
  • A report submitted but its reference never recorded in the complaint file, so the two records cannot be connected.
  • Adverse event screens left blank, so it cannot be shown the screening step was performed at all.
  • Complaints closed late with extensions approved after the due date, or with no extension record at all.
  • Trending performed but by raw count, or with lot-level complaints divided by total product distribution.
  • A threshold crossed with no traceable consequence, or a threshold quietly raised in the review that it triggered.
  • A reportability matrix that has not kept up with new markets or new products.
  • No reconciliation between the complaint system and the safety database, so a case dropped between them would never be found.
  • Cross-references between complaint, deviation, CAPA, safety, and recall records that do not resolve, or that point one way only.
  • A self-inspection programme that samples only tidy closed files and therefore always passes.

How to adapt this checklist

  1. Set the document number, owner, frequency, and reviewer-independence rule in the header. The independence rule matters: a coordinator reviewing their own files will not find these failure modes.
  2. Set the sample size and the selection minimums in section 1.1 to your complaint volume. The proportions matter more than the total. If you receive 40 complaints a year, review all of them and drop the sampling table.
  3. Align every line to your own SOP. Where your procedure requires something this checklist does not test, add a line. Where a line tests something your procedure does not require, either add the requirement or remove the line, but do not leave a checklist testing against a standard you have not adopted.
  4. Set your own numeric limits in section 2.4 and 2.5 (backlog age, on-time closure, agreement rate, “other” share). The values in the specimen are illustrative.
  5. Decide which lines are critical for your products and mark them, rather than inheriting the asterisks here. For a sterile parenteral, the sterility and field action lines carry more weight than they would for a solid oral dose.
  6. Run it against real files before an inspection is announced, not after. The findings here take weeks to close, and closing them under inspection pressure is how retrospective documentation gets created.
  7. Route findings that appear in more than one file to CAPA as systemic, not to the individual handler. A failure mode across multiple handlers is a procedure or form design problem.
  8. Feed the results into management review with a trend across reviews, so the programme can show whether it is improving.
  9. Confirm every regulation referenced in the governing documents against the current published version before issue.
Use madhadi.com as an app Full screen, works offline, one tap from your home screen.